projectindustrialbuzz.com

India’s PLI Scheme for Pharma Achieves Key Milestones: 48 Projects Approved to Boost API Self-Sufficiency.

Govt reports ₹4,254 cr investment under API PLI scheme, creating domestic capacity for 25 critical drug ingredients with ₹412 cr exports.

Government Reports Significant Progress in Reducing Critical Drug Ingredient Imports

New Delhi, July 2024: The Indian government has approved 48 strategic projects under its Production Linked Incentive (PLI) scheme for Key Starting Materials (KSMs), Drug Intermediates (DIs), and Active Pharmaceutical Ingredients (APIs), marking a crucial step toward reducing the country’s dependence on imported pharmaceutical raw materials.

Key Achievements of PLI Scheme for Pharmaceuticals (as of December 2024)

MetricTargetAchievement% Completion
Approved Projects4848100%
Investment Commitment₹3,938.5 cr₹4,254 cr108%
Cumulative Sales₹1,556 cr
Import Substitution₹1,144 cr
Export Earnings₹412 cr
API/KSMs Covered2525100%

Strategic Impact on Pharmaceutical Sector

1. Critical Supply Chain Resilience

✔ 25 previously imported APIs/KSMs now manufactured domestically
✔ Reduced single-source dependency from China (previously 70%+ imports)
✔ Enhanced drug security for essential medicines including:

2. Financial Performance Exceeding Targets

3. Employment & Capacity Building

👨🔬 High-skilled jobs: 8,500+ in technical roles
🏭 MSME Participation: 32 of 48 projects by small/mid-sized firms
🔬 Technology Transfer: 14 patented processes indigenized

Scheme Implementation & Industry Outreach

Multi-Channel Awareness Campaign

🌐 Digital Engagement:

Geographical Distribution

📍 Top 5 States:

  1. Gujarat (14 projects)
  2. Maharashtra (11 projects)
  3. Andhra Pradesh (7 projects)
  4. Himachal Pradesh (6 projects)
  5. Telangana (5 projects)

Ministerial Statement

Anupriya Patel, MoS Chemicals & Fertilizers:
“This PLI initiative has transformed India from being ‘pharmacy of the world’ to becoming ‘laboratory of the world’. Our ₹1,144 crore import substitution already demonstrates strategic success in essential drug security.”

Future Roadmap

🔹 Phase-2 Expansion: 15 more APIs being considered
🔹 Cluster Development: 3 API parks under construction
🔹 R&D Boost: 5% additional incentive for novel process development

Global Context


Exit mobile version